The National Center for Tumor Diseases (NCT) is funding the multicenter CURE-GvHD study, led by Uniklinikum Erlangen, with €2.5 million from the Federal Ministry of Research, Technology, and Space. A CAR-T cell approach is being evaluated for patients with severe chronic graft-versus-host disease (cGvHD). Allogeneic blood stem cell transplantation, the transfer of donated stem cells… Source
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.